Announcements Trials
Browse Landscape

Phase

Phase 2 39Phase 1 21Phase 3 20Phase 1/2 11Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Breast Neoplasms 10Stomach Neoplasms 8Prostatic Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Lung Neoplasms 4Gastrointestinal Neoplasms 3Neoplasms 2Head and Neck Neoplasms 2HER2-positive Breast Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Squamous Cell Non-small Cell Lung Cancer 1Recurrent Squamous Cell Lung Carcinoma 1Recurrence 1Progression Free Survival 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lymphoid Interstitial Pneumonia 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1HER2-negative Breast Cancer 1FGFR1 Gene Amplification 1

Interventions

Gemcitabine 5Capecitabine 4pembrolizumab 3Fluorouracil 3Cisplatin 3vinflunine 2enzalutamide 2cabazitaxel 2abiraterone 2Ipilimumab 2Haloperidol 2Androgen Antagonists 2vedolizumab 1trifluridine tipiracil drug combination 1relugolix 1racemetyrosine 1nimotuzumab 1nilutamide 1lanreotide 1histrelin 1futibatinib 1exemestane 1dexamethasone acetate 1dexamethasone 21-phosphate 1bicalutamide 1beta-Glucans 1auricularum 1atezolizumab 1apatinib 1apalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoplasm Metastasis × Docetaxel × Clear all
NCT00401323 2011-01-20

Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Sanofi

Phase 2/3 Completed
568 enrolled
Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local

Data powered by HemOnc (CC BY 4.0) Colophon âš¡